Evidence map›Paper›PMID 42472000›Full record

ArticleMolecular therapy. Oncology2026

Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma.

Federica Ghersa, Caitlin Yung, Ester Molina, Hisae Kuoch, Colin Caine, Karina Krotova, Antonella Borgatti, George Aslanidi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Federica GhersaThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Caitlin YungUniversity of Minnesota College of Veterinary Medicine, St Paul, MN 55108, USA.
Ester MolinaThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Hisae KuochThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Colin CaineThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Karina KrotovaThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Antonella BorgattiUniversity of Minnesota College of Veterinary Medicine, St Paul, MN 55108, USA.
George AslanidiThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.

Funding

Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.R01CA285620 · UNIVERSITY OF MINNESOTA · 2025 to 2025
$488k
NCI NIH HHS R01 CA285620
6 · The paper itself

Abstract

Like humans, companion dogs develop cancers spontaneously in the context of increased age, genetic variations, or environmental exposures, making them valuable as a preclinical model. Here, we assessed the safety and preliminary effectiveness of a multivalent adeno-associated virus (AAV) cancer vaccine in spontaneous canine oral melanoma. Eight companion dogs were vaccinated with equal doses of three different optimized AAV vectors encoding the melanoma others glycoprotein 100 (GP100), tyrosinase (Tyr), and tyrosinase-related protein 1 (TRP-1). Five dogs received a dose of 3 × 10

Indexed as

adeno-associated virusantigen-specific T cellscancer vaccinecanine modelprotective immune response

Identifiers

PMID42472000
PMCPMC13380433

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.